Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung

Basit Öğe Kaydı
dc.contributor.authorGoss, G.
dc.contributor.authorFelip, E.
dc.contributor.authorCobo, M.
dc.contributor.authorLu, S.
dc.contributor.authorSyrigos, K.
dc.contributor.authorLee, K. H.
dc.contributor.authorGoker, E.
dc.contributor.authorGeorgoulias, V.
dc.contributor.authorLi, W.
dc.contributor.authorGuclu, S.
dc.contributor.authorIsla, D.
dc.contributor.authorMin, Y. Joo
dc.contributor.authorMorabito, A.
dc.contributor.authorArdizzoni, A.
dc.contributor.authorGadgeel, S.
dc.contributor.authorGibson, N.
dc.contributor.authorKraemer, N.
dc.contributor.authorSolca, F.
dc.contributor.authorCseh, A.
dc.contributor.authorEhrnrooth, E.
dc.contributor.authorSoria, J.
dc.date.accessioned2019-10-27T11:04:55Z
dc.date.available2019-10-27T11:04:55Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.identifier.doi10.1016/j.jtho.2017.09.1484
dc.identifier.endpageS2218en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue11en_US
dc.identifier.startpageS2217en_US
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2017.09.1484
dc.identifier.urihttps://hdl.handle.net/11454/31561
dc.identifier.volume12en_US
dc.identifier.wosWOS:000463860802083en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNSCLCen_US
dc.subjectSquamous cell carcinomaen_US
dc.subjectafatiniben_US
dc.titleImpact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lungen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu